Filing Flows › UroGen Pharma (URGN) › How it makes money
How UroGen Pharma (URGN) makes money
UroGen Pharma (URGN) made $89.0M of revenue in the third quarter 2026 (Q3 2026), +224% from a year earlier. Zusduri brought in $68.0M (76%); Jelmyto brought in $21.0M (24%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Zusduri | $68.0M | 76.5% | +35% | 38× |
| Jelmyto | $21.0M | 23.5% | -5% | -18% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $89.0M | 100.0% |
| Income tax | $1.0M | 1.1% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $89.0M | +224% |
| Q2 2026 | $72.5M | +199% |
| Q1 2026 | $51.0M | +152% |
| Q4 2025 | $37.8M | +54% |
| Q3 2025 | $27.5M | +9% |
| Q2 2025 | $24.2M | +11% |
| Q1 2025 | $20.3M | +8% |
From UroGen Pharma's 10-Q filed Nov 4, 2026 (on EDGAR).
Questions
How does UroGen Pharma make money?
UroGen Pharma (URGN) made $89.0M of revenue in the third quarter 2026 (Q3 2026), +224% from a year earlier. Zusduri brought in $68.0M (76%); Jelmyto brought in $21.0M (24%).
What is UroGen Pharma's biggest business?
Zusduri: $68.0M in the third quarter 2026, 76% of revenue, up 38-fold from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.